| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A 68930 hydrochloride | 130465-39-3 | sc-203485 sc-203485A | 10 mg 50 mg | $176.00 $733.00 | 2 | |
A-68930 is a DPP7 inhibitor with a mechanism that likely involves binding to the active site of the enzyme. This binding inhibits the proteolytic activity of DPP7, affecting its role in peptide metabolism and potentially impacting immune responses. | ||||||
Vildagliptin | 274901-16-5 | sc-208485 | 10 mg | $176.00 | 4 | |
Vildagliptin is a DPP-4 inhibitor with potential DPP7 inhibitory activity. Its mechanism involves blocking the degradation of incretin hormones, which can enhance insulin secretion. While its DPP7 inhibition is less pronounced, it may affect peptide metabolism to some extent. | ||||||
Diprotin A | 90614-48-5 | sc-497890 | 5 mg | $292.00 | ||
Diprotin A is a tripeptide aldehyde that acts as a competitive inhibitor of DPP7. By binding to the enzyme's active site, it hinders substrate binding and cleavage, potentially influencing the degradation of specific peptides and immune responses. | ||||||
Canagliflozin | 842133-18-0 | sc-364454 sc-364454A | 5 mg 50 mg | $312.00 $416.00 | 2 | |
TA-7284 is a DPP7 inhibitor that likely binds to the enzyme's active site. This binding interferes with DPP7's proteolytic activity, impacting the degradation of certain peptides and potentially modulating immune responses and other related processes. | ||||||
Dipeptidylpeptidase IV Inhibitor IV, K579 | 440100-64-1 | sc-202583 | 5 mg | $235.00 | 3 | |
K-579 is a small molecule inhibitor of DPP7 that likely functions by binding to the enzyme's active site. By inhibiting DPP7's enzymatic activity, it may influence the degradation of specific peptides and their roles in immune regulation and inflammation. | ||||||
Dapagliflozin | 461432-26-8 | sc-364481 sc-364481A sc-364481B | 5 mg 50 mg 1 g | $117.00 $428.00 $1051.00 | 6 | |
Dapagliflozin may have off-target effects on DPP7 due to structural similarities. Its mechanism involves reducing glucose reabsorption in the kidneys but may impact DPP7-related processes to some extent. | ||||||